Recombinant Factor VIII for the Treatment of Previously Untreated Patients with Hemophilia A – Safety, Efficacy, and Development of Inhibitors

New England Journal of Medicine

Volumn 328, Issue 7, 1993, Pages 453-459

  Lusher, Jeanne M ^a   Arkin, Steven ^b   Abildgaard, Charles F ^c   Schwartz, Richard S ^d  

^a CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d BAYER AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8 INHIBITOR; RECOMBINANT BLOOD CLOTTING FACTOR 8;

ARTICLE; BLEEDING; CHILD; ERYTHEMA; HEMOPHILIA A; HUMAN; INFANT; MAJOR CLINICAL STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROPHYLAXIS; URTICARIA;

ANTIBODIES; ANTIBODY FORMATION; FACTOR VIII; HEMOPHILIA A; HUMAN; INFANT; RECOMBINANT PROTEINS; SUPPORT, NON-U.S. GOV'T; TIME FACTORS;

EID: 0027473752     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199302183280701     Document Type: Article

References (36)

1. Azzi A, Ciappi S, Zakvrzewska K, Morfini M, Mariani G, Mannucci PM Human parvovirus B19 infection in hemophiliacs first infused with two high-purity, virally attenuated factor VIII concentrates. Am J Hematol 1992; 39:228-230
2. Lyon DJ, Chapman CS, Martin C, Symptomatic parvovirus B19 infection and heat-treated factor IX concentrate. Lancet 1989; 1:1085-1085
3. Berntorp E, Nilsson IM, Ljung R, Widell A Hepatitis C virus transmission by monoclonal antibody purified factor VIII concentrate. Lancet 1990; 335:1531-1532
4. Mannucci PM, Zanetti AR, Colombo M, Antibody to hepatitis C virus after a vapor-treated factor VIII concentrate. Thromb Haemost 1990; 64:232-234
5. Lusher JM, Transfusion Safety Study Group. Hepatitis C virus (HCV) transmission with clotting factor concentrates in current use. Blood 1991; 78: Suppl 1: 1409-1409 abstract.
6. Kleim JP, Bailly E, Schneweis KE, Acute HIV-1 infection in patients with hemophilia B treated with β-propriolactone-UV-inactivated clotting factor. Thromb Haemost 1990; 64:336-337
7. White GC II, McMillan CW, Kingdon HS, Shoemaker CB Use of recombinant antihemophilic factor in the treatment of two patients with classic hemophilia. N Engl J Med 1989; 320:166-170
8. Schwartz RS, Abildgaard CF, Aledort LM, Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A. N Engl J Med 1990; 323:1800-1805
9. Chan SY, Lembach KJ Genetic characterization of recombinant BHK-21 cells expressing factor VIII. Semin Hematol 1991; 28: Suppl 1: 10-16
10. Klein U Production and characterization of recombinant Factor VIII. Semin Hematol 1991; 28: Suppl 1: 17-21
11. Kasper CK, Aledort LM, Counts RB, A more uniform measurement of Factor VIII inhibitors. Thromb Diath Haemorrh 1975; 34:869-872
12. Hoyer LW, Gawryl MS, de la Fuente B Immunochemical characterization of factor VIII inhibitors. Prog Clin Biol Res 1984; 150:73-85
13. Fulcher CA, de Graaf Mahoney S, Zimmerman TS FVIII inhibitor IgG subclass and FVIII polypeptide specificity determined by immunoblotting. Blood 1987; 69:1475-1480
14. Kaplan EL, Meier P Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457-481
15. Wilcoxon F Individual comparisons by ranking methods. Biom Bull 1945; 1:80-83
16. Brackmann HH, Gormsen J Massive factor-VIII infusion in haemophiliac with factor-VIII inhibitor, high responder. Lancet 1977; 2:933-933
17. Ewing NP, Sanders NL, Dietrich SL, Kasper CK Induction of immune tolerance to factor VIII in hemophiliacs with inhibitors. JAMA 1988; 259:65-68
18. Scandella D, Mattingly M, de Graaf S, Fulcher CA Localization of epitopes for human factor VIII inhibitor antibodies by immunoblotting and antibody neutralization. Blood 1989; 74:1618-1626
19. Hoyer LW Immunochemical properties of factor VIII and factor IX inhibitors. Blood Coagul Fibrinolysis 1991; 2: Suppl 1: 11-15
20. Lusher JM Factor VIII inhibitors: etiology, characterization, natural history, and management. Ann N Y Acad Sci 1987; 509:89-102
21. Lusher JM Current perspectives on the significance and interpretation of factor VIII and factor IX inhibitors. Blood Coagul Fibrinolysis 1991; 2: Suppl 1: 1-3
22. Gill FM The natural history of factor VIII inhibitors in patients with hemophilia A. Prog Clin Biol Res 1984; 150:19-29
23. White GC II, McMillan CW, Blatt PM, Roberts HR Factor VIII inhibitors: a clinical overview. Am J Hematol 1982; 13:335-342
24. McMillan CW, Shapiro SS, Whitehurst D, The natural history of factor VIII:C inhibitors in patients with hemophilia A: a national cooperative study. II. Observations on the initial development of factor VIII:C inhibitors. Blood 1988; 71:344-348
25. Mannucci PM, Colombo M Revision of the protocol recommended for studies of safety from hepatitis of clotting factor concentrates. Thromb Haemost 1989; 61:532-534
26. Lusher JM, Salzman PM, Monoclate Study Group. Viral safety and inhibitor development associated with factor VIIIC ultra-purified from plasma in hemophiliacs previously unexposed to factor VIIIC concentrates. Semin Hematol 1990; 27: Suppl 2: 1-7
27. Lusher JM Viral safety and inhibitor development associated with monoclonal antibody-purified F VIII C. Ann Hematol 1991; 63:138-141
28. Addiego JE Jr, Gomperts E, Liu S-L, Treatment of hemophilia A with a highly purified factor VIII concentrate prepared by anti-FVIIIc immunoaffinity chromatography. Thromb Haemost 1992; 67:19-27
29. Ehrenforth S, Kreuz W, Scharrer I, Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992; 339:594-598
30. Buchanan G, Johnson A. High frequency of factor VIII inhibitors in infants and young boys recently diagnosed as having severe factor VIII deficiency. Presented at the 43rd Annual Meeting of the National Hemophilia Foundation, Tampa, Fla., October 8-12, 1991. abstract.
31. Schwarzinger I, Pabinger I, Korninger C, Incidence of inhibitors in patients with severe and moderate hemophilia A treated with factor VIII concentrates. Am J Hematol 1987; 24:241-245
32. Rasi V, Ikkala E Haemophiliacs with factor VIII inhibitors in Finland: prevalence, incidence and outcome. Br J Haematol 1990; 76:369-371
33. Rizza CR, Matthews JM Effect of frequent factor VIII replacement on the level of factor VIII antibodies in haemophiliacs. Br J Haematol 1982; 52:13-24
34. Vermylen J, Peerlinck K Epidemic of factor VIII inhibitors linked to factor VIII-P. Acta Clin Belg 1991; 46:419-420
35. Roberts HR Antigenicity of highly purified factor VIII concentrates. Blood Coagul Fibrinolysis 1991; 2: Suppl 1: 17-19
36. Fournel MA Preclinical and in vitro studies of recombinant factor VIII. Semin Hematol 1991; 28: Suppl 1: 22-26